Results from the S-TRAC study were presented at the European Society of Medical Oncology (ESMO) congress in Copenhagen this week. The results show that Sutent (sunitinib) improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse.
In the phase III S-TRAC trial, patients were followed for 5 years after taking either Sutent or placebo for one year. Median disease-free survival in the Sutent arm was 6.8 years, versus 5.6 years for placebo, an improvement of more than a year.
S-TRAC is also the first positive adjuvant renal cell cancer trial ever, and “a very important, really paradigm-changing, treatment-changing trial for these patients.”